Cervical cancer remains a major public health challenge in India, causing around 80,000 annual deaths. Fortunately, a newly validated indigenous HPV test offers a major breakthrough in affordable diagnostics. The World Health Organization (WHO) recommends transitioning to molecular testing to eliminate this disease. Therefore, integrating these cost-effective tools is critical for expanding screening coverage nationwide.

The Need for an Indigenous HPV Test in India

Currently, visual inspection with acetic acid (VIA) is the standard method in many areas. However, this screening method has subjective limitations and low sensitivity. Although global gold-standard DNA tests are highly accurate, they remain too expensive for last-mile clinical settings. Consequently, healthcare providers struggle to screen women in remote villages. This new indigenous HPV test addresses these gaps by providing highly reliable results at a fraction of the cost.

Validating the New Point-of-Care Platforms

A recent multicentre study evaluated Indian HPV DNA testing platforms under international standards. Specifically, premier institutions like AIIMS New Delhi and ICMR conducted this research. The investigators collaborated closely with the WHO International Agency for Research on Cancer (IARC). Ultimately, the study confirmed that these tests achieve clinical validation comparable to global standards. Thus, India can now deploy these tools in national screening programs with high confidence.

Scalability and Future Clinical Directions

These molecular platforms target the eight most common high-risk HPV types. Moreover, district-level personnel can run them easily since they already use similar PCR systems. Additionally, clinicians can adopt same-day treatment protocols for patients who test positive. In the future, self-sampling and high-throughput adaptations will further enhance patient access. Consequently, this diagnostic innovation will significantly accelerate cervical cancer elimination goals.

Frequently Asked Questions

Q1: Why is the indigenous HPV test preferred over traditional VIA screening?

The molecular test specifically detects high-risk human papillomavirus DNA with objective clinical accuracy. Conversely, traditional visual inspection with acetic acid relies heavily on provider interpretation and has lower sensitivity.

Q2: At what ages should women undergo HPV DNA screening?

According to the WHO elimination strategy, women should undergo screening at age 35 and again at age 45. Using validated tests, these two rounds are sufficient to achieve elimination goals.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Low-cost Indigenous HPV test may improve cervical cancer screening access inIndia - ETHealthworld


2. Ramírez AT, Clifford GM, Dillner J, Kuhn L, Arbyn M, Bhatla N, et al. Reflections regarding validation of new HPV tests with reduced HPV genotypes: report from an IARC expert consultation. J Med Virol. 2025;e70310.